## **GILEAD SCIENCES INC.**

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Company

GILEAD
Creating Possible

**2024/07/15** 22:00:00

**Price 70.81**USD

Difference 2


1.21%(0.85)

**Contact Details** 

GILEAD SCIENCES INC. Tel: +1-650-574-3000 -- Fax: +1-650-522-5853

333 Lakeside Drive Web: <a href="http://www.gilead.com">http://www.gilead.com</a>

94404 Foster City E-mail: -



# **Company Profile**

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

### Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	22	20:	21
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	16,085,000,000		14,443,000,000		14,772,000,000	
Common stock capital		1,000,000		1,000,000		1,000,000
Fixed assets	46,040,000,000		48,728,000,000		53,180,000,000	
Equity capital of a company		22,749,000,000		21,209,000,000		21,064,000,000
Cash and cash equivalents	6,085,000,000		5,412,000,000		5,338,000,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		11,280,000,000		11,237,000,000		11,610,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		28,096,000,000		30,725,000,000		35,278,000,000
Different income		-		-		-
Other liabilities		2,773,000,000		5,095,000,000		5,254,000,000
Total assets	62,125,000,000	62,125,000,000	63,171,000,000	63,171,000,000	67,952,000,000	67,952,000,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	18,000	17,000	14,400
Equity ratio	36.48%	33.52%	30.99%
Debt-equity ratio	174.10%	198.29%	222.67%

### **Others**

	2023	2022	2021
Tax Expense Rate	18.18%	21.47%	25.09%

# **GILEAD SCIENCES INC.**

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	27,058,000,000	27,085,000,000	27,372,000,000
Net income	5,664,000,000	4,592,000,000	6,225,000,000
EBIT	6,810,559,000	6,188,833,000	8,508,843,000
Operating income before taxes	6,859,000,000	5,814,000,000	8,278,000,000
Cash Flow	8,006,000,000	9,072,000,000	11,384,000,000
Net interest income	-568,000,000	-935,000,000	-1,001,000,000
Research and development expenses	5,758,000,000	4,998,000,000	5,363,000,000
Income taxes	1,247,000,000	1,248,000,000	2,077,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	1,378,455	1,460,997	1,743,064

## **Board of Directors**

lember of Board of Directors
lember of Board of Directors
lember of Board of Directors
hairman of Managing Board
lember of Executive Committee
֡